Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Dar Global

    MCap

    USD1,486m

    Last close

    USD8.25

    ▲ 0.00 (0.00%)

    Theon International

    MCap

    EUR866m

    Last close

    EUR12.36

    ▲ −0.14 (−1.12%)

    Metals One

    MCap

    GBP2m

    Last close

    GBP0.00

    ▲ −0.06 (−12.24%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Polyphor – executive interview

Polyphor – executive interview

Polyphor is a development-stage company focused on oncology and antibiotics. Its lead programme is balixafortide, a CXCR4 inhibitor currently in Phase III for breast cancer. Data are expected in 2021. The company plans to start its Phase I programme of inhaled murepavadin to treat P. aeruginosa infections in CF patients by the year end.

In this interview, CEO Gokhan Batur provides an overview of the company’s programmes, especially balixafortide and inhaled murepavadin. He also reviews the Phase Ib data for balixafortide, as well as the design and timelines for the Phase III data expected next year.

< Previous
Next >

You may also be interested in these:

Investment Companies

Vantage: Gresham House Energy Storage Fund – Navigating challenges in energy storage

TMT

IP Group – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free